Tumor Cells, Tumor DNA and Immunological Response in Colonic Stent Placement
NCT ID: NCT03546569
Last Updated: 2021-02-25
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
20 participants
OBSERVATIONAL
2018-05-01
2021-02-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Furthermore, we intend to study the opportunity to identify patients with a higher risk of recurrence due to the SEMS placement by monitoring cfDNA and ctDNA-levels, as it may be a potential biomarker to initiate or optimize chemotherapy and thereby ensure a better prognosis for the patients.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Plasma ctDNA in Patients Undergoing Diagnostic Colonoscopy
NCT02665299
OPTIMIzation of Treatment SElection and Follow up in Oligometastatic Colorectal Cancer
NCT04680260
IMPROVE: Circulating Tumor DNA Analysis to Optimize Treatment for Patients With Colorectal Cancer
NCT03637686
Smart Measurement of Circulating Tumor DNA
NCT06989814
Colonic Stent and Tumor Cell Dissemination
NCT01628328
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Prior to SEMS placement:
When potential candidates are admitted to the hospital they will be presented to the study by the relevant surgeon. The investigators will be contacted, when the patient is admitted to hospital.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients with acute malignant obstruction in the colon.
* ASA class I-III (Classification of the American Society of Anesthesiology)
* Signed informed consent
Exclusion Criteria
* Withdrawal of informed consent
* Bloodtransfusion 24 hours prior to stent-placement until 24 hours after stent-placement.
* Surgery within 24 hours after stent-placement
* Known inflammatory bowel disease
18 Years
95 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Zealand University Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Zealand University Hospital
Køge, , Denmark
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
REG-059-2017
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.